Body composition and quality of life as markers of the efficacy of growth hormone replacement therapy in adults

Horm Res. 2001;55 Suppl 2:55-60. doi: 10.1159/000063476.


Growth hormone (GH) replacement therapy in GH-deficient adults should be initiated with a low dose, independent of body weight or body surface area. Measurements of serum insulin-like growth factor I (IGF-I) concentrations, as well as clinical examinations aimed at detecting signs of fluid excess, are important as safety markers to avoid overtreatment with GH. At present, there is no optimal marker for the long-term efficacy of GH replacement therapy. The long-term maintenance dose of GH should, therefore, be titrated in each individual based on the clinical response, with the aim of normalizing body hydration, other measurements of body composition, quality of life and well-being, and biochemical indices such as serum IGF-I concentration.

Publication types

  • Review

MeSH terms

  • Adult
  • Biomarkers
  • Body Composition*
  • Growth Hormone / administration & dosage
  • Growth Hormone / adverse effects
  • Growth Hormone / therapeutic use*
  • Hormone Replacement Therapy*
  • Humans
  • Outcome Assessment, Health Care / methods*
  • Quality of Life*


  • Biomarkers
  • Growth Hormone